Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Up 260.9% in June

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 208,401 shares, a growth of 260.9% from the May 31st total of 57,741 shares. Based on an average trading volume of 1,239,748 shares, the short-interest ratio is presently 0.2 days. Approximately 1.9% of the shares of the company are short sold.

Hong Kong Pharma Digital Technology Stock Performance

Hong Kong Pharma Digital Technology stock traded down $0.01 during mid-day trading on Friday, reaching $0.36. The company had a trading volume of 14,700 shares, compared to its average volume of 760,880. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.93 and a quick ratio of 2.73. The company has a 50 day moving average of $0.54 and a 200-day moving average of $0.66. Hong Kong Pharma Digital Technology has a 52 week low of $0.32 and a 52 week high of $2.58.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Hong Kong Pharma Digital Technology

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.